Anti-angiogenic therapy in the management of retinopathy of prematurity

Developments in Ophthalmology

Volumn 44, Issue , 2009, Pages 89-97

  Drenser, Kimberly A ^a,b,c  

^a ASSOCIATED RETINAL CONSULTANTS   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651229379     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000223949     Document Type: Article

References (19)

1. Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684- 1694.
2. Sonmez K, Drenser KA, Capone A Jr, Trese MT: Vitreous levels of stromal cell-derived factor-1 and vascular endothelial growth factor in patients with retinopathy of prematurity: implications for vascular activity. Ophthalmology 2008;115:1065-1070.
3. Stone J, Itin A, Alon T, et al: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
4. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL: Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 2008;49:3107-3114.
5. Pierce EA, Avery RL, Foley ED, et al: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovas-cularization. Proc Natl Acad Sci USA 1995;92: 905-909.
6. Smith LE: Retinopathy of prematurity. Angiogenesis 2007;10:133-140.
7. Kychenthal A, Dorta P, Katz X: Zone 1 retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 2006;26:S11-S15.
8. Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Swietochowska E, Siemińska L, Kajdaniuk D, Głogowska-Szelag J, Nowak K: A comparison of the levels of hepatocyte growth factor in serum in patients with type 1 diabetes mellitus with different stages of diabetic retinopathy. Endokrynol Pol 2008; 59:2-5.
9. Simó R, Carrasco E, García-Ramírez M, Hernández C: Angiogenic and antiangiogenic factors in prolif-erative diabetic retinopathy. Curr Diabetes Rev 2006;2:71-98.
10. Inokuchi N, Ikeda T, Imamura Y, Sotozono C, Kinoshita S, Uchihori Y, Nakamura K: Vitreous levels of insulin-like growth factor-I in patients with proliferative diabetic retinopathy. Curr Eye Res 2001; 23:368-371.
11. Hernández C, Carrasco E, García-Arumí J, Maria Segura R, Simó R: Intravitreous levels of hepatocyte growth factor/scatter factor and vascular cell adhesion molecule-1 in the vitreous fluid of diabetic patients with proliferative retinopathy. Diabetes Metab 2004;30:341-346.
12. Sieczkiewicz GJ, Herman IM: TGF-beta 1 signaling controls retinal pericyte contractile protein expression. Microvasc Res 2003;66:190-196.
13. Mintz-Hittner HA, Kuffel RR Jr: Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-838.
14. Chung EJ, Kim JH, Ahn HS, Koh HJ: Combination of laser photocoagulation and intravitreal bevaci-zumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730.
15. Honda S, Hirabayashi H, Tsukahara Y, Negi A: Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063.
16. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG: Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216.
17. Tranos P, Gemenetzi M, Papandroudis A, Chrisafis C, Papadakos D: Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. Eye 2008;22:862.
18. Boulton M, Gregor Z, McLeod D, et al: Intravitreal growth factors in proliferative diabetic retinopathy. Br J Ophthalmol 1997;81:228-233.
19. Kato M, Yoshimura S, Kokuzawa J, et al: Hepatocyte growth factor promotes neuronal differentiation of neural stem cells derived from embryonic stem cells. Regener Transplant 2004;15:5-8.